This led to development of the phase 1 trial of IL-15 combined with alemtuzumab for patients with adult T cell leukemia (NCT02689453) as well as ongoing trials in chronic lymphocytic leukemia (NCT03759184, NCT03905135). The gene discussed is IL15; the disease is adult T-cell leukemia/lymphoma.